• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Host innate immune mechanisms separating inflammatory or lymphoproliferative diseases in HTLV-1 infection

Research Project

Project/Area Number 20K07512
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 49060:Virology-related
Research InstitutionKansai Medical University (2022)
Tokyo Medical and Dental University (2020-2021)

Principal Investigator

KANNAGI Mari  関西医科大学, 医学部, 教授 (80202034)

Project Period (FY) 2020-04-01 – 2023-03-31
Project Status Completed (Fiscal Year 2022)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2022: ¥390,000 (Direct Cost: ¥300,000、Indirect Cost: ¥90,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2020: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
KeywordsHTLV-1 / 自然免疫 / 腫瘍 / 炎症 / ATL / EZH2 / Lenalidomide / STAT3 / ウイルス
Outline of Research at the Start

ヒトT細胞白血病ウイルスI型(HTLV-1)は悪性腫瘍である成人T細胞白血病(ATL)と慢性炎症性の神経難病であるHTLV-1随伴脊髄症(HAM)を起こす。両者は全く異なる疾患であるが、ウイルス側には大きな違いが無く何が両疾患を分けているのか分かっていない。これまでの我々の研究から、HTLV-1持続感染における腫瘍と炎症を分ける要因に自然免疫応答が関与していることが推測される。本研究では、HTLV-1感染における自然免疫応答の役割を明らかにし疾患機序を解明する。これらが解明されれば、発症リスク予知に役立ち、その制御は新たな治療方法や発症予防方法の開発につながる。

Outline of Final Research Achievements

Human T-cell leukemia virus type 1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in separate groups of HTLV-1-infected individuals. In our previous study, we suggested that the IL-10-STAT3 pathway could be a candidate of host factors that separate malignant tumor and inflammation. In this study, we aimed to find factors regulating IL-10-STAT3 pathway in HTLV-1-infected cells. Among the reagents used as a probe, Lenalidomide suppressed IL-10-STAT3 pathway in HTLV-1-infected cells. Unexpectedly, Lenalidomide also suppressed EZH2, an epigenetic regulator known to promote oncogenesis. Lenalidomide is an immunomoduratory drug that has been used to treat multiple myeloma and recently been approved for relapsed /recurrent ATL. Our results not only indicate the importance of IL-10-STAT3 pathway in tumor development in HTLV-1 infection, but also discovered a new link between Lenalidomide and epigenetic regulation.

Academic Significance and Societal Importance of the Research Achievements

Lenalidomideは再発・難治ATLの治療薬としてすでに承認されているがその機序には不明点が多い。ATLに一定の効果を示すLenalidomideがSTAT3経路を抑制したことは、STAT3経路がHTLV-1感染からATLへの進展に重要であることを裏付けている。さらに、このSTAT3経路の調節にEZH2が関与している可能性が示唆された。また、Lenalidomideは多発性骨髄腫にも汎用される薬剤であるが、EZH2を負に制御しエピジェネティックな作用を持つことは今回初めて明らかになった知見であり、Lenalidomideのような免疫調節薬の多彩な作用を説明する新たな機序と考えられる。

Report

(4 results)
  • 2022 Annual Research Report   Final Research Report ( PDF )
  • 2021 Research-status Report
  • 2020 Research-status Report
  • Research Products

    (12 results)

All 2023 2022 2021 2020

All Journal Article (4 results) (of which Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (8 results) (of which Int'l Joint Research: 1 results,  Invited: 1 results)

  • [Journal Article] Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.2023

    • Author(s)
      Hasegawa A, Murata M, Fujikawa T, Katagiri K, Nagano Y, Masuda T, Kuramitsu M, Nakajima S, Fujisawa J, Okuma K, Grover P, Kidiga M, Akari H, Kannagi M.
    • Journal Title

      PLoS Pathogens

      Volume: 19 Issue: 2 Pages: e1011104-e1011104

    • DOI

      10.1371/journal.ppat.1011104

    • Related Report
      2022 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells2021

    • Author(s)
      Kondo Nobuyo, Nagano Yoshiko, Hasegawa Atsuhiko, Ishizawa Miku, Katagiri Kuniko, Yoneda Takeru, Masuda Takao, Kannagi Mari
    • Journal Title

      Biochem. Biophys. Res. Commun.

      Volume: 574 Pages: 104-109

    • DOI

      10.1016/j.bbrc.2021.08.051

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Short‐term cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Tax‐specific CTL response in adult T‐cell leukemia patients2021

    • Author(s)
      Ishizawa Miku、Ganbaatar Undrakh、Hasegawa Atsuhiko、Takatsuka Natsuko、Kondo Nobuyo、Yoneda Takeru、Katagiri Kuniko、Masuda Takao、Utsunomiya Atae、Kannagi Mari
    • Journal Title

      Cancer Science

      Volume: 112 Issue: 3 Pages: 1161-1172

    • DOI

      10.1111/cas.14800

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] HTLV-1感染に対するワクチン開発の展望2020

    • Author(s)
      神奈木真理、末廣陽子、長谷川温彦
    • Journal Title

      周産期医学

      Volume: 50 Pages: 1707-1712

    • Related Report
      2020 Research-status Report
  • [Presentation] 1.Potential anti-ATL therapeutic vaccine using short-term cultured autologous peripheral blood mononuclear cells: preclinical evidence in vitro and in vivo.2022

    • Author(s)
      Kannagi M, Hasegawa A, Utsunomiya A, Akari H.
    • Organizer
      20th International Conference on Human Retrovirology: HTLV and Related Viruses.
    • Related Report
      2022 Annual Research Report
    • Int'l Joint Research
  • [Presentation] IMiDs (lenalidomide and pomalidomide) suppress HTLV-1-infected cell growth through EZH2 inhibition.2022

    • Author(s)
      Kannagi M, Kondo N, Nagano Y, Masuda T, Hasegawa A.
    • Organizer
      第81回日本癌学会学術総会
    • Related Report
      2022 Annual Research Report
  • [Presentation] STLV-1特異的CTLの低応答性を示すSTLV-1自然感染ニホンザルに対する自家末梢血単核球の免疫接種によるCTL応答の回復.2022

    • Author(s)
      神奈木 真理、長谷川 温彦、村田 めぐみ、中嶋 伸介、藤澤 順一、大隈 和、明里 宏文
    • Organizer
      第69回ウイルス学会
    • Related Report
      2022 Annual Research Report
  • [Presentation] HDAC阻害剤はATL細胞の免疫原性を増大し抗腫瘍Tax特異的CTL応答を活性化させる.2021

    • Author(s)
      石澤 未来、長谷川 温彦、高塚 奈津子、近藤 伸世、米田 建、片桐 邦子、増田 貴夫、宇都宮 與、神奈木 真理.
    • Organizer
      第7回日本HTLV-1学会
    • Related Report
      2021 Research-status Report
  • [Presentation] 免疫調節薬LenalidomideによるHTLV-1感染細胞の増殖抑制にはEZH2阻害が関与する.2021

    • Author(s)
      近藤伸世、永野佳子、長谷川温彦、石澤未来、片桐邦子、米田 建、増田貴夫、神奈木真理
    • Organizer
      第7回日本HTLV-1学会
    • Related Report
      2021 Research-status Report
  • [Presentation] 成人T細胞白血病患者の自家PBMCを免疫原とした抗腫瘍Tax特異的CTL応答の惹起.2021

    • Author(s)
      神奈木 真理, 石澤 未来、Undrakh Ganbaata, 長谷川 温彦、高塚 奈津子、近藤 伸世、米田 建、片桐 邦子、増田 貴夫、宇都宮 與.
    • Organizer
      第25回日本がん免疫学会総会
    • Related Report
      2021 Research-status Report
  • [Presentation] 成人T細胞白血病の免疫学的疾患機序の解明ならびにワクチン療法の開発2021

    • Author(s)
      神奈木 真理
    • Organizer
      第80回日本癌学会
    • Related Report
      2021 Research-status Report
    • Invited
  • [Presentation] Restoration of impaired STLV-1-specific CTL response in STLV-1-infected Japanese macaques by a CTL-based vaccine.2020

    • Author(s)
      Hasegawa, A., Murata, M., Fujikawa, T., Nagano, Y., Akari, H., Kannagi, M
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi